What is peptide‑receptor radionuclide therapy (PRRT) in a patient receiving continuous venovenous hemodialysis (CVHD)?

PRRT on CVHD: Administration and Management

Peptide receptor radionuclide therapy (PRRT) can be administered to patients requiring continuous venovenous hemodialysis (CVHD), with dialysis performed at 24 hours post-administration to clear the radionuclide and minimize nephrotoxicity while preserving any remaining renal function. 1

What is PRRT?

PRRT is a molecularly targeted radiation therapy involving systemic administration of radiolabeled peptides (typically ¹⁷⁷Lu-DOTATATE or ⁹⁰Y-DOTATOC) that bind with high affinity to somatostatin receptor subtype 2 (sstr2) overexpressed on neuroendocrine tumor cells 2. The therapy delivers cytotoxic beta-particle radiation directly to tumor cells, achieving objective responses in up to 30% of patients with metastatic or inoperable neuroendocrine tumors, with improved survival and quality of life 2.

Critical Renal Considerations

The kidneys are critical organs at risk during PRRT because proximal tubular reabsorption and interstitial retention of radiopeptides result in excessive renal irradiation 2. This nephrotoxicity risk is particularly relevant for patients already on renal replacement therapy.

Standard Renal Protection Protocol

For patients with functioning kidneys, amino acid infusions (L-lysine and/or L-arginine) are co-administered to competitively inhibit proximal tubular reabsorption, reducing renal absorbed dose by 9-53% 2. The protocol involves:

• 25 g amino acids diluted in 1 L normal saline
• Infusion started 30-60 minutes before radiopeptide administration
• Continued over 4 hours minimum
• Antiemetic premedication (5-HT3 antagonist or corticosteroid) 2

PRRT in Patients on Dialysis

Evidence for Dialysis Support

Recent case reports demonstrate successful PRRT administration in patients with severe chronic kidney disease (CKD stage 4, eGFR 15-29 mL/min) and end-stage renal disease on hemodialysis 1. The key management strategy involves:

• Dialysis timing: Perform hemodialysis at 24 hours post-¹⁷⁷Lu-DOTATATE administration 1
• Use temporary central venous catheter for dialysis access
• Employ renal dosimetry and whole-body retention analysis to minimize nephrotoxicity
• Consider 50% dose reduction in patients with eGFR 30-50 mL/min 1

Important Caveats

• Original NETTER-1 trial excluded patients with creatinine clearance <50 mL/min 1
• No formal safety data exists for patients with eGFR <30 mL/min or end-stage renal failure 1
• Treatment decisions must be individualized on a case-by-case basis with multidisciplinary input
• Volume overload must be avoided in patients with cardiac insufficiency (e.g., carcinoid heart valve disease) 2

Practical Implementation for CVHD Patients

When administering PRRT to a patient on CVHD:

1. Coordinate with nephrology and radiation safety teams to plan dialysis timing
2. Administer PRRT with standard antiemetic premedication (amino acid infusion may be modified or omitted given lack of tubular function)
3. Initiate or continue CVHD at 24 hours post-administration to clear circulating radionuclide 1
4. Monitor for hematological toxicity (bone marrow is the other critical organ at risk) 2
5. Ensure appropriate radiation safety protocols for dialysis staff and waste management

Radiation Safety Considerations

The facility must have appropriate personnel, radiation safety equipment, and procedures for waste management and handling accidental contamination 2. ¹⁷⁷Lu emits gamma radiation (113 keV and 208 keV), allowing for post-treatment imaging and dosimetry assessments 2.

Clinical Outcomes

PRRT demonstrates significant survival benefits in gastroenteropancreatic neuroendocrine tumors, with improved progression-free survival (32.4 vs 11.0 months) and overall survival (49.8 vs 38.4 months) compared to other therapies after surgical progression 3. The therapy also preserves quality of life and can ameliorate functioning syndrome symptoms 4.